Premium
Use of JAK inhibitors in the management of myelofibrosis: a revision of the B ritish C ommittee for S tandards in H aematology G uidelines for I nvestigation and M anagement of M yelofibrosis 2012
Author(s) -
Reilly John T.,
McMullin Mary Frances,
Beer Philip A.,
Butt Nauman,
Conneally Eibhlin,
Duncombe Andrew S.,
Green Anthony R.,
Mikhaeel George,
Gilleece Marie H.,
Knapper Steven,
Mead Adam J.,
Mesa Ruben A.,
Sekhar Mallika,
Harrison Claire N.
Publication year - 2014
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12985
Subject(s) - ruxolitinib , myelofibrosis , medicine , hazard ratio , calreticulin , confidence interval , hematology , oncology , biology , bone marrow , genetics , endoplasmic reticulum
Reilly, John T., McMullin, Mary Frances, Beer, Philip A., Butt, Nauman, Conneally, Eibhlin, Duncombe, Andrew S., Green, Anthony R., Mikhaeel, George, Gilleece, Marie H., Knapper, Steven, Mead, Adam J., Mesa, Ruben A., Sekhar, Mallika and Harrison, Claire N. 2014. Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. British Journal of Haematology 167 (3) , pp. 418-420. 10.1111/bjh.12985 file